Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence

Conclusions: Elafin predicts poor outcome in breast and ovarian cancer patients delineates a subset of endocrine receptor positive breast cancer patients susceptible to recurrence whom could benefit from more aggressive intervention. Our in vitro results suggest that elafin arrests cell luminal breast cancer cells, perhaps suggesting a role in tumor dormancy.
Source: Breast Cancer Research - Category: Cancer & Oncology Authors: Source Type: research